[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Subscription::
News& Events::
Contact us::
Site Facilities::
Ethics & Permissions::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Indexing
                        
..
:: Volume 21, Issue 1 (Spring 2024) ::
Sci J Iran Blood Transfus Organ 2024, 21(1): 21-32 Back to browse issues page
Comparison of combined chelation therapy effects (deferoxamine-deferiprone, deferoxamine-deferasirox) with Deferoxamine and Deferasirox in beta-thalassemia major in Yasuj
P. Etemad far , A. Azizi , J.M. Malekzadeh , M. Saghazadeh , O.S. Esmaeili , M. Parsian , F. Rad
Abstract:   (156 Views)
Abstract
Background and Objectives
Chelation therapy is essential for beta-thalassemia major. This study aims to determine the complications clinical and laboratory symptoms of monotherapy and combined treatment of iron chelators in beta-thalassemia major patients in Yasuj.

Materials and Methods
In this cross-sectional-descriptive-analytical study, 103 patients with beta-thalassemia major in Yasuj city were evaluated during 2021-2022. After collecting the demographic, clinical and laboratory information of the patients, the results were reported as mean ± standard deviation and percentage. The degree of statistical differences between ratios was calculated using the Kruskal-Wallis test.

Results
The average age of our patients was reported to be 24.74 ± 8.34 years. 54.4% (n = 56) of the study patients were men and 45.6% (n = 47) were women. The results of the present study showed that there was a statistically significant difference in mean ferritin among different study groups (p = 0.028). Patients treated with deferoxamine showed the highest mean serum ferritin (5925.5 ± 3397ng%) and patients who took deferoxamine together with deferiprone or deferasirox had a lower mean ferritin compared to deferoxamine alone  (3348 ± 2560, 4269 ± 3322 ng%), respectively. Also, the present study showed that after taking iron removers, 47.6% of patients (n = 49) had no clinical complications and 52.4% (n = 54) had at least one complication.

Conclusions 
Our results showed that Deferoxamine can have a great effect in reducing iron deposition and serum ferritin levels in combination with oral drugs.
 
Keywords: Key words: beta-Thalassemia Major, Iron Chelating Agents, Deferoxamine, Deferasirox, Drug Therapy, Combination ​​​​​​​
Full-Text [PDF 588 kb]   (61 Downloads) |   |   Full-Text (HTML)  (23 Views)  
Type of Study: Research | Subject: Hematology
Published: 2024/03/29
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Etemad far P, Azizi A, Malekzadeh J, Saghazadeh M, Esmaeili O, Parsian M et al . Comparison of combined chelation therapy effects (deferoxamine-deferiprone, deferoxamine-deferasirox) with Deferoxamine and Deferasirox in beta-thalassemia major in Yasuj. Sci J Iran Blood Transfus Organ 2024; 21 (1) :21-32
URL: http://bloodjournal.ir/article-1-1511-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 21, Issue 1 (Spring 2024) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.06 seconds with 39 queries by YEKTAWEB 4645